Xcovery SHP2 Inhibitor IND Approved by US FDA
PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational New Drug application (IND) of BPI-442096 , a small molecule Src homology region 2 domain-containing phosphatase 2 (SHP2) inhibitor, in solid tumors. Xcovery will initiate a phase I clinical … [Read more…]
